Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Akari Therapeutics, Plc is a biotechnology business based in the US. Akari Therapeutics shares (AKTX) are listed on the NASDAQ and all prices are listed in US Dollars. Akari Therapeutics employs 10 staff and has a market cap (total outstanding shares value) of USD$123.1 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
52-week range | USD$0.87 - USD$4.21 |
---|---|
50-day moving average | USD$2.7424 |
200-day moving average | USD$1.9839 |
Wall St. target price | USD$5 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-0.874 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Gross profit TTM | USD$0 |
---|---|
Return on assets TTM | -92.41% |
Return on equity TTM | -447.36% |
Profit margin | 0% |
Book value | $0.143 |
Market capitalisation | USD$123.1 million |
TTM: trailing 12 months
There are currently 158,031 Akari Therapeutics shares held short by investors – that's known as Akari Therapeutics's "short interest". This figure is 16.7% down from 189,747 last month.
There are a few different ways that this level of interest in shorting Akari Therapeutics shares can be evaluated.
Akari Therapeutics's "short interest ratio" (SIR) is the quantity of Akari Therapeutics shares currently shorted divided by the average quantity of Akari Therapeutics shares traded daily (recently around 405207.69230769). Akari Therapeutics's SIR currently stands at 0.39. In other words for every 100,000 Akari Therapeutics shares traded daily on the market, roughly 390 shares are currently held short.
However Akari Therapeutics's short interest can also be evaluated against the total number of Akari Therapeutics shares, or, against the total number of tradable Akari Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Akari Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Akari Therapeutics shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Akari Therapeutics shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Akari Therapeutics.
Find out more about how you can short Akari Therapeutics stock.
We're not expecting Akari Therapeutics to pay a dividend over the next 12 months.
Akari Therapeutics's shares were split on a 1:10 basis on 17 September 2015. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Akari Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Akari Therapeutics shares which in turn could have impacted Akari Therapeutics's share price.
Over the last 12 months, Akari Therapeutics's shares have ranged in value from as little as $0.87 up to $4.21. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akari Therapeutics's is 1.4424. This would suggest that Akari Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics, Plc is based in London, the United Kingdom.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.